In Brief: Cygnus/Yamanouchi
This article was originally published in The Gray Sheet
Executive Summary
Cygnus/Yamanouchi: Sign marketing and distribution agreement under which Tokyo-based Yamanouchi Pharmaceutical gains exclusive rights to sell the GlucoWatch continuous glucose monitoring device in Japan and Korea. According to terms of the deal, Redwood City, California-based Cygnus will have "primary responsibility" for completing product development and for manufacturing. Cygnus could receive up to $10 mil. in up-front and milestone payments under the deal; the agreement also includes royalties. In a pact announced in February, Cygnus licensed GlucoWatch to Becton Dickinson for all markets except Japan and Korea ("The Gray Sheet" Feb. 19, I&W-9)...